May 15, 2013 Cynapsus Publishes White Paper on Apomorphine for ‘Off’ Periods in Parkinson's Disease and Its Alternative Delivery Development Candidate APL-130277 Read More >		May 9, 2013 Cynapsus Announces Completion of Short Form Prospectus Offering Read More >
		May 9, 2013 Cynapsus Therapeutics Appoints Two New Directors Read More >		May 1, 2013 Cynapsus Therapeutics Grants Stock Options Read More >
		April 26, 2013 Cynapsus Therapeutics Reports 2012 Financial Results and Highlights Key Developments Read More >		March 21, 2013 Cynapsus Raises Additional $1.3 Million As Part Of Short Form Prospectus Offering Read More >
				Press Release Archive

Cynapsus is a specialty pharmaceutical company developing the only non-injectable (i.e. sublingual) delivery of the only approved drug (apomorphine) to be used as a rescue therapy for “off” motor symptoms of Parkinson’s disease. Over one million people in the U.S. and an estimated 5 million people globally suffer from Parkinson's disease. Parkinson’s disease is a chronic and progressive neurodegenerative disease that impacts motor activity, and its prevalence is increasing with the aging of the population.